Chronic Obstructive Pulmonary Disease Treatment Devices Market

Chronic Obstructive Pulmonary Disease Treatment Devices Market By Product Type (Inhalers [Dry Powder Inhaler, Metred Dose Inhaler, And Soft Mist Inhalers] And Nebulizers [Compressor Nebulizer, Ultrasonic Nebulizer, And Mesh Nebulizer]), By End-User (Hospitals & Clinics, Homecare Settings, And Other End-Users), by geography is expected to grow at a steady CAGR forecast till 2027 owing to growing prevalence of chronic obstructive pulmonary diseases due to long-term exposure to air pollution, secondhand smoke & dust, fumes & chemicals and rise in consumption of tobacco among youth population

 

Global chronic obstructive pulmonary disease (COPD) treatment devices market is estimated to grow at a CAGR of 6.37% during the forecast period from 2022 to 2027. The increase in demand for chronic obstructive pulmonary disease treatment devices is primarily attributed to the rising exposure to air pollution, airborne particles, chemicals & fumes, secondhand smoke, industrial chemicals and dust owing to which the prevalence of COPD is increasing globally. Further, rise in consumption of tobacco among youth population will increase the risk of respiratory disorders like COPD, asthma ultimately leading to propel the demand of COPD treating devices. Additionally, the burgeoning demand for short-term and effective treatment in case of attacks, technological advancements in the devices such as production of ideal aerosol particle size & property of providing higher amount of dose, and others, and increasing awareness about the symptoms and treatment of disorders like COPD and asthma across the world are anticipated to bolster the market, thereby contributing to the growth of the chronic obstructive pulmonary disease treatment devices market during the forecast period from 2022-2027.

Chronic Obstructive Pulmonary Disease Treatment Devices Market Dynamics:

The chronic obstructive pulmonary disease treatment devices market is witnessing a growth in product demand owing to various reasons such as the growing prevalence of COPD due to long-term exposure to air pollution, secondhand smoke and dust, fumes and chemicals. Furthermore, rise in consumption of tobacco among youth population is anticipated to bolster the market for chronic obstructive pulmonary disease treatment devices during the forecast period.

 

For instance, according to the data published by World Health Organization (WHO) 2022, it was estimated that COPD was the third leading cause of death worldwide, causing 3.23 million deaths in the year 2019. Additionally, nearly 90% of COPD deaths were those in patients under 70 years of age in low- and middle-income countries. Moreover, COPD causes persistent and progressive respiratory symptoms, including difficulty in breathing, cough and phlegm production. The disorder results from long-term exposure to harmful gases and particles combined with individual factors, including events which influence lung growth in childhood and genetics. Early diagnosis and treatment, including smoking cessation support is required to slow down the incidence and mortality rate from the disease. However, the increasing prevalence of COPD will increase the demand of treatment devices such as inhalers and nebulizers, thereby expected to propel the overall market growth of the COPD treatment devices in the forecast period of 2022 – 2027.

 

Moreover, according to American Lung Association, State of Tobacco Control 2022, a 2021 study found that menthol cigarettes were responsible for 1.5 million new smokers among African Americans in 2021. The study concluded that from 2019 to 2021, disposable e-cigarette use skyrocketed by more than 23 times among high school e-cigarette users (from 2.4% to 55.8%) and more than 14 times among middle school e-cigarette users (from 3% to 43.8%). Additionally, according to National Youth Tobacco Survey 2020, it was estimated that in 2019-2020 more than 23.6% of high school students in the U.S. use at least one tobacco product, including e-cigarettes. As per the same source, smoking is the number one preventable cause of death in the U.S. killing over 480,000 people per year. Furthermore, COPD is usually caused by cigarette smoking, though long-term exposure to other lung irritants, like secondhand smoke, can also contribute to COPD. Smoking damages the air sacs, airways, and the lining of the lungs making it sensitive for COPD and other respiratory disorders. Smoking is also a trigger for COPD flare-ups. Injured lungs have trouble moving enough air in and out, so it's hard to breathe; one of the major symptoms of COPD. Moreover, smoking and secondhand smoke exposure during childhood and teenage years can slow lung growth and development. The rising consumption of smoking globally will increase the prevalence of COPD, leading to the surging demand of the treatment devices ultimately bolstering the overall market growth of COPD treating devices.

 

However, high cost of chronic obstructive pulmonary disease treatment devices, stringent government regulations, and environmental concerns associated with metered dose inhalers (MDI) may be certain limiting factors of the chronic obstructive pulmonary disease treatment devices market growth.

 

The ongoing COVID-19 pandemic had a drastic positive impact on the chronic obstructive pulmonary disease treatment devices market owing to rising burden of the respiratory diseases in COVID-19 pandemic as the viral infection severely affects the lungs. Moreover, it is estimated that people may develop respiratory illness such as COPD and others as an after effect which will surge the demand for the devices among the COVID recovering patients. However, due to strict lockdown restrictions there were disruption in the supply chain leading to unavailability of raw materials halting the manufacturing process. This lead to shortage of device and higher prices of device in the market. However, with masses being vaccinated, and resumption of the cross border trade and supply chain, and with the increasing demand the key players of the chronic obstructive pulmonary disease treatment devices market increased their manufacturing across the world are anticipated to bolster the market, thereby contributing to the growth of the chronic obstructive pulmonary disease treatment devices market during the forecast period from 2022-2027.

Chronic Obstructive Pulmonary Disease Treatment Devices Market Segment Analysis:

Chronic Obstructive Pulmonary Disease Treatment Devices Market by Product Type (Inhalers [Dry Powder Inhaler, Metered Dose Inhaler, and Soft Mist Inhalers] and Nebulizers [Compressor Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer]), by End-User (Hospitals & Clinics, Homecare Settings, and Other End Users) and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).

 

In the product type segment of the chronic obstructive pulmonary disease treatment devices market, the soft mist inhalers is estimated to hold a higher share in the chronic obstructive pulmonary disease treatment devices market in the year 2021. This can be ascribed to the wide benefit circle that is associated with the soft mist inhalers.

 

The soft mist inhalers is one of the newer type of device. It creates a cloud of medicine that a patient can inhale without the help of a propellant. The mist in the inhaler contains more particles than the other types of inhalers.

 

Moreover, the spray in the soft mist inhalers leaves the inhaler more slowly leading to more of the drug into the lungs. Additionally, as the mist comes out slowly so the device doesn’t require any coordination while inhaling the drug. A spacer is also unnecessary in case of soft mist inhalers.

 

Further, the soft mist inhaler is portable and comes with a combination of drug molecules available in the market. The inhaler is inspiratory flow independent, no maximum flow is required at the time of the deliver and comes with once-daily dosing.

 

Moreover, the product launches in local market, in turn, drive the product demand in the market. For instance, in December 2021, Boehringer Ingelheim, one of the world's largest pharmaceutical companies, announced the launch of the Respimat® reusable inhaler in Ireland. The inhaler is a soft mist, reusable inhaler used with up to six refill cartridges. It is a propellant-free inhaler. By using the reusable inhaler with six refill cartridges the product carbon footprint is reduced by 71%. The inhaler delivers the chronic obstructive pulmonary disease (COPD) as well as the asthma medication.

 

Thus, owing to the wide advantages as well as product launch in the local market will increase the demand of soft mist inhalers, which in turn will drive the overall chronic obstructive pulmonary disease treatment devices market growth.

North America is expected to dominate the overall Chronic Obstructive Pulmonary Disease Treatment Devices Market:

Among all the regions, North America is expected to account for the largest share in the global Chronic Obstructive Pulmonary Disease Treatment Devices market. Growing prevalence of chronic obstructive pulmonary disease due to exposure to air pollution, airborne particles, chemicals & fumes, secondhand smoke, industrial chemicals & dust and rise in consumption of tobacco among youth population will drive the demand for chronic obstructive pulmonary disease treatment devices in the forecast period. Further, government initiations to create the awareness of diagnosis and treatment of COPD, leading to increased demand of treatment devices in the market. Thus, leading to a rise in the overall North America chronic obstructive pulmonary disease treatment devices market growth.

 

For instance, according the Center for Disease Control and Prevention (CDC) 2020, it was estimated that percentage of COPD, emphysema, or chronic bronchitis for adults aged 18 and over in the United States in the year 2020 was 5.0%. Moreover, according Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Report 2022, reported that the prevalence of COPD is higher in smokers & ex-smokers as compared to non-smokers in the United States. The morbidity of COPD may be affected by other chronic diseases such as, cardiovascular diseases, musculoskeletal impairment, diabetes, and others that are related to smoking, age and genetics. Additionally, as per CDC 2020, the number of deaths in the year 2020 due to bronchitis was nearly 457 in US. Further, emphysema deaths in the year 2020 in US was nearly 7,425. The increasing prevalence and mortality rate can be slowed down by giving proper treatment to the patients by using the treatment devices such as, inhalers and nebulizers, ultimately leading to increase demand of COPD treating devices. Thus, the increasing prevalence of COPD in the United States is anticipated to bolster the COPD treatment devices market in the forecast period, thereby increasing the overall market growth in the North America.

 

Furthermore, according to United States Environmental Protection Agency 2021, in the year 2021, it was calculated that about 67 million tons of pollution were emitted into the atmosphere in the United States. Breathing in air pollutants can irritate the airways and may cause shortness of breath, coughing, and wheezing. People with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) are vulnerable to the detrimental effects of air pollutants. Air pollution can induce the acute exacerbation of COPD and can increase the respiratory morbidity and mortality. The increasing air pollution may increase the incidence and exacerbation of COPD, leading to the increased demand of COPD treating devices like inhalers and nebulizers in the market. Thus, increasing the market of the devices in the forecast period 2022 – 2027. Therefore, propelling the overall market growth of the chronic obstructive pulmonary disease treatment devices in the North America.

 

Thus, all the above-mentioned factors will collectively contribute to the chronic obstructive pulmonary disease treatment devices market growth in the North America region.

Chronic Obstructive Pulmonary Disease Treatment Devices Market Key Players:

Some of the key market players operating in the chronic obstructive pulmonary disease treatment devices market include Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, PARI GmbH, GF Health Products, Inc., BMC Medical Co., Ltd., Medtronic PLC, Invacare Corporation, Trudell Medical International, Nouvag AG, Timesco Healthcare Ltd., LAICA S.p.A., Vega Technologies Inc., Besco Medical Limited, DeVilbiss Healthcare LLC, Feellife Health Inc., Wellinks, Rossmax International Ltd., Novartis AG, AstraZeneca, GlaxoSmithKline plc, Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, LepuMedical Technology(Beijing)Co.,Ltd., Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc., Microlife Corporation, Honsun, among others.

Recent Developmental Activities in the Chronic Obstructive Pulmonary Disease Treatment Devices Market:

  • In August 2021, Lupin Healthcare Limited, wholly-owned subsidiary of global pharma major Lupin Limited, announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Luforbec® (beclometasone/formoterol) 100/6 dose pressurized metered dose inhaler (pMDI) for the patients in the UK. Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD).
  • In January 2021, Wellinks, the nebulizer’s developer, announced that the wireless nebulizer for use by people with chronic obstructive pulmonary disease (COPD) has been cleared by a review board of the U.S. Food and Drug Administration (FDA).
  • In October 2020, Zydus Cadila, Indian multinational pharmaceutical company, announced that they had launched Forglyn pMDI, a pressurized Metered Dose Inhaler (pMDI) with a combination of Long Acting Muscarinic Antagonist (LAMA) and Long Acting Beta Agonist (LABA) for patients suffering from Chronic Obstructive Pulmonary Disease (COPD) in India.
  • In July 2020, AstraZeneca’s, a global, science-led biopharmaceutical company, announced that its Breztri Aerosphere inhaler has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Key Takeaways from the Chronic Obstructive Pulmonary Disease Treatment Devices Market Report Study

  • Market size analysis for current chronic obstructive pulmonary disease treatment devices market size (2021), and market forecast for 5 years (2022-2027)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the chronic obstructive pulmonary disease treatment devices market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global chronic obstructive pulmonary disease treatment devices market.
  • Various opportunities available for the other competitor in the chronic obstructive pulmonary disease treatment devices market space.
  • What are the top performing segments in 2021? How these segments will perform in 2027.
  • Which is the top-performing regions and countries in the current chronic obstructive pulmonary disease treatment devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for chronic obstructive pulmonary disease treatment devices market growth in the coming future?

Target Audience who can be benefited from this Chronic Obstructive Pulmonary Disease Treatment Devices Market Report Study

  • Chronic obstructive pulmonary disease treatment devices providers
  • Research organizations and consulting companies
  • Chronic obstructive pulmonary disease treatment devices-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in chronic obstructive pulmonary disease treatment devices
  • Various End-users who want to know more about the chronic obstructive pulmonary disease treatment devices market and latest technological developments in the chronic obstructive pulmonary disease treatment devices market.

Frequently Asked Questions for Chronic Obstructive Pulmonary Disease Treatment Devices Market:

1. What are Chronic Obstructive Pulmonary Disease Treatment Devices?

Chronic obstructive pulmonary disease treatment devices are the medical devices or tools used by a patient to treat the symptoms of chronic obstructive pulmonary disease. The medication to treat COPD is administrated through a device such as, inhalers, used to get relief from the symptoms of the disease.

 

2. What is the market for Global Chronic Obstructive Pulmonary Disease Treatment Devices?

Global chronic obstructive pulmonary disease (COPD) treatment devices market is estimated to grow at a CAGR of 6.37% during the forecast period from 2022 to 2027.

 

3. What are the drivers for the Global Chronic Obstructive Pulmonary Disease Treatment Devices market?

The chronic obstructive pulmonary disease treatment devices market is witnessing a positive market growth owing to growing prevalence of chronic obstructive pulmonary disease, rise in consumption of tobacco among youth population, increasing exposure to chemicals, pollution, airborne particles, and others, and burgeoning demand for short-term and effective treatment in case of attacks across the world are anticipated to bolster the market.

 

4. Who are the key players operating in the Global Chronic Obstructive Pulmonary Disease Treatment Devices market?

Some of the key market players operating in the chronic obstructive pulmonary disease treatment devices market include Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, PARI GmbH, GF Health Products, Inc., BMC Medical Co., Ltd., Medtronic PLC, Invacare Corporation, Trudell Medical International, Nouvag AG, Timesco Healthcare Ltd., LAICA S.p.A., Vega Technologies Inc., Besco Medical Limited, DeVilbiss Healthcare LLC, Feellife Health Inc., Wellinks, Rossmax International Ltd., Novartis AG, AstraZeneca, GlaxoSmithKline plc, Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, LepuMedical Technology(Beijing)Co.,Ltd., Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc., Microlife Corporation, Honsun and others.

 

5. Which region has the highest share in Chronic Obstructive Pulmonary Disease Treatment Devices Market?

North America is expected to hold the highest revenue share in the chronic obstructive pulmonary disease treatment devices market during the forecast period. Growing prevalence of chronic obstructive pulmonary disease and rise in consumption of tobacco among youth population, will increase the demand for chronic obstructive pulmonary disease treatment devices in North America, leading to a rise in the overall chronic obstructive pulmonary disease treatment devices market growth in this region.

1. Chronic Obstructive Pulmonary Disease Treatment Devices Market Report Introduction

2. Chronic Obstructive Pulmonary Disease Treatment Devices Market Executive Summary

2.1. Scope of the Study

2.2. Market at Glance

2.3. Competitive Assessment

3. Regulatory Analysis

3.1. The United States

3.2. Europe

3.3. Japan

3.4. China

4. Chronic Obstructive Pulmonary Disease Treatment Devices Market Key Factors Analysis

4.1. Chronic Obstructive Pulmonary Disease Treatment Devices Market Drivers

4.1.1. Growing Prevalence of Chronic Obstructive Pulmonary Disease Due to Increasing Exposure to Chemicals, Pollution, Airborne Particles, and Others

4.1.2. Rise in Consumption of Tobacco Among Youth Population

4.1.3. Burgeoning Demand for Short-Term and Effective Treatment in Case of Attacks

4.1.4. Technological Advancements in the Devices Such as Production of Ideal Aerosol Particle Size

4.2. Chronic Obstructive Pulmonary Disease Treatment Devices Market Restraints and Challenges

4.2.1. High Cost of Chronic Obstructive Pulmonary Disease Treatment Devices

4.2.2. Stringent Government Regulations

4.2.3. Environmental Concerns Associated with Metered Dose Inhalers (MDI)

4.3. Chronic Obstructive Pulmonary Disease Treatment Devices Market Opportunities

4.3.1. Increasing Awareness and Demand of Portable Inhalation Devices

4.3.2. Rising Government Initiatives Toward the Spread of Awareness for COPD and Asthma Symptoms

5. Chronic Obstructive Pulmonary Disease Treatment Devices Market Porter’s Five Forces Analysis

5.1. Bargaining Power of Suppliers

5.2. Bargaining Power of Consumers

5.3. Threat of New Entrants

5.4. Threat of Substitutes

5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Chronic Obstructive Pulmonary Disease Treatment Devices Market

7. Chronic Obstructive Pulmonary Disease Treatment Devices Market Layout

7.1. By Product Type

7.1.1. Inhalers

7.1.1.1. Dry Powder Inhaler

7.1.1.2. Metered Dose Inhaler

7.1.1.3. Soft Mist Inhalers

7.1.2. Nebulizers

7.1.2.1. Compressor Nebulizer

7.1.2.2. Ultrasonic Nebulizer

7.1.2.3. Mesh Nebulizer

7.2. By End-User

7.2.1. Hospitals & Clinics

7.2.2. Homecare Settings

7.2.3. Others

7.3. By Geography

7.3.1. North America

7.3.1.1. United States

7.3.1.2. Canada

7.3.1.3. Mexico

7.3.2. Europe  

7.3.2.1. France

7.3.2.2. Germany

7.3.2.3. United Kingdom

7.3.2.4. Italy

7.3.2.5. Spain

7.3.2.6. Rest of Europe

7.3.3. Asia-Pacific

7.3.3.1. China

7.3.3.2. Japan

7.3.3.3. India

7.3.3.4. Australia

7.3.3.5. South Korea

7.3.3.6. Rest of Asia Pacific

7.3.4. Rest of the World (RoW) 

8. Chronic Obstructive Pulmonary Disease Treatment Devices Market Global Company Share Analysis – Key 3-5 Companies

9. Chronic Obstructive Pulmonary Disease Treatment Devices Market Company and Product Profiles

9.1. Koninklijke Philips N.V.

9.1.1. Company Overview

9.1.2. Company Snapshot

9.1.3. Financial Overview

9.1.4. Product Listing

9.1.5. Entropy

9.2. Omron Healthcare, Inc.

9.2.1. Company Overview

9.2.2. Company Snapshot

9.2.3. Financial Overview

9.2.4. Product Listing

9.2.5. Entropy

9.3. Aerogen

9.3.1. Company Overview

9.3.2. Company Snapshot

9.3.3. Financial Overview

9.3.4. Product Listing

9.3.5. Entropy

9.4. PARI GmbH

9.4.1. Company Overview

9.4.2. Company Snapshot

9.4.3. Financial Overview

9.4.4. Product Listing

9.4.5. Entropy

9.5. GF Health Products, Inc.

9.5.1. Company Overview

9.5.2. Company Snapshot

9.5.3. Financial Overview

9.5.4. Product Listing

9.5.5. Entropy

9.6. BMC Medical Co., Ltd.

9.6.1. Company Overview

9.6.2. Company Snapshot

9.6.3. Financial Overview

9.6.4. Product Listing

9.6.5. Entropy

9.7. Medtronic PLC

9.7.1. Company Overview

9.7.2. Company Snapshot

9.7.3. Financial Overview

9.7.4. Product Listing

9.7.5. Entropy

9.8. Invacare Corporation

9.8.1. Company Overview

9.8.2. Company Snapshot

9.8.3. Financial Overview

9.8.4. Product Listing

9.8.5. Entropy

9.9. Trudell Medical International

9.9.1. Company Overview

9.9.2. Company Snapshot

9.9.3. Financial Overview

9.9.4. Product Listing

9.9.5. Entropy

9.10. Nouvag AG

9.10.1. Company Overview

9.10.2. Company Snapshot

9.10.3. Financial Overview

9.10.4. Product Listing

9.10.5. Entropy

9.11. Timesco Healthcare Ltd.

9.11.1. Company Overview

9.11.2. Company Snapshot

9.11.3. Financial Overview

9.11.4. Product Listing

9.11.5. Entropy

9.12. LAICA S.p.A.

9.12.1. Company Overview

9.12.2. Company Snapshot

9.12.3. Financial Overview

9.12.4. Product Listing

9.12.5. Entropy

9.13. Vega Technologies Inc.

9.13.1. Company Overview

9.13.2. Company Snapshot

9.13.3. Financial Overview

9.13.4. Product Listing

9.13.5. Entropy

9.14. Besco Medical Limited

9.14.1. Company Overview

9.14.2. Company Snapshot

9.14.3. Financial Overview

9.14.4. Product Listing

9.14.5. Entropy

9.15. DeVilbiss Healthcare LLC

9.15.1. Company Overview

9.15.2. Company Snapshot

9.15.3. Financial Overview

9.15.4. Product Listing

9.15.5. Entropy

9.16. Feellife Health Inc.

9.16.1. Company Overview

9.16.2. Company Snapshot

9.16.3. Financial Overview

9.16.4. Product Listing

9.16.5. Entropy

9.17. Wellinks

9.17.1. Company Overview

9.17.2. Company Snapshot

9.17.3. Financial Overview

9.17.4. Product Listing

9.17.5. Entropy

9.18. Rossmax International Ltd

9.18.1. Company Overview

9.18.2. Company Snapshot

9.18.3. Financial Overview

9.18.4. Product Listing

9.18.5. Entropy

9.19. Novartis AG

9.19.1. Company Overview

9.19.2. Company Snapshot

9.19.3. Financial Overview

9.19.4. Product Listing

9.19.5. Entropy

9.20. AstraZeneca

9.20.1. Company Overview

9.20.2. Company Snapshot

9.20.3. Financial Overview

9.20.4. Product Listing

9.20.5. Entropy

9.21. GlaxoSmithKline plc

9.21.1. Company Overview

9.21.2. Company Snapshot

9.21.3. Financial Overview

9.21.4. Product Listing

9.21.5. Entropy

9.21.5. Entropy

9.22. Lupin

9.22.1. Company Overview

9.22.2. Company Snapshot

9.22.3. Financial Overview

9.22.4. Product Listing

9.22.5. Entropy

9.23. Zydus Cadila

9.23.1. Company Overview

9.23.2. Company Snapshot

9.23.3. Financial Overview

9.23.4. Product Listing

9.23.5. Entropy

9.24. Teva Pharmaceutical Industries Ltd.

9.24.1. Company Overview

9.24.2. Company Snapshot

9.24.3. Financial Overview

9.24.4. Product Listing

9.24.5. Entropy

9.25. Boehringer Ingelheim International GmbH

9.25.1. Company Overview

9.25.2. Company Snapshot

9.25.3. Financial Overview

9.25.4. Product Listing

9.25.5. Entropy

9.26. Glenmark Pharmaceuticals Limited

9.26.1. Company Overview

9.26.2. Company Snapshot

9.26.3. Financial Overview

9.26.4. Product Listing

9.26.5. Entropy

9.27. Lepu Medical Technology (Beijing) Co., Ltd.

9.27.1. Company Overview

9.27.2. Company Snapshot

9.27.3. Financial Overview

9.27.4. Product Listing

9.27.5. Entropy

9.28. Promed Technology Co. Limited

9.28.1. Company Overview

9.28.2. Company Snapshot

9.28.3. Financial Overview

9.28.4. Product Listing

9.28.5. Entropy

9.29. HELTMAN Medikal A.S.

9.29.1. Company Overview

9.29.2. Company Snapshot

9.29.3. Financial Overview

9.29.4. Product Listing

9.29.5. Entropy

9.30. Pneuma Respiratory

9.30.1. Company Overview

9.30.2. Company Snapshot

9.30.3. Financial Overview

9.30.4. Product Listing

9.30.5. Entropy

9.31. Cipla Inc.

9.31.1. Company Overview

9.31.2. Company Snapshot

9.31.3. Financial Overview

9.31.4. Product Listing

9.31.5. Entropy

9.32. Microlife Corporation

9.32.1. Company Overview

9.32.2. Company Snapshot

9.32.3. Financial Overview

9.32.4. Product Listing

9.32.5. Entropy

9.33. Honsun

9.33.1. Company Overview

9.33.2. Company Snapshot

9.33.3. Financial Overview

9.33.4. Product Listing

9.33.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Table

Table 1: Competitive Analysis

Table 2: COVID-19 Impact Analysis

Table 3: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global (2019-2027)

Table 4: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global by Product Type (2019-2027)

Table 5: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global by End User (2019-2027)

Table 6: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global by Geography (2019-2027)

Table 7: Chronic Obstructive Pulmonary Disease Treatment Devices Market in North America (2019-2027)

Table 8: Chronic Obstructive Pulmonary Disease Treatment Devices Market in North America by Country (2019-2027)

Table 9: Chronic Obstructive Pulmonary Disease Treatment Devices Market in the US (2019-2027)

Table 10: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Canada (2019-2027)

Table 11: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Mexico (2019-2027)

Table 12: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Europe (2019-2027)

Table 13: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Europe by Country (2019-2027)

Table 14: Chronic Obstructive Pulmonary Disease Treatment Devices Market in France (2019-2027)

Table 15: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Germany (2019-2027)

Table 16: Chronic Obstructive Pulmonary Disease Treatment Devices Market in the United Kingdom (2019-2027)

Table 17: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Italy (2019-2027)

Table 18: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Spain (2019-2027)

Table 19: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Russia (2019-2027)

Table 20: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Rest of Europe (2019-2027)

Table 21: Chronic Obstructive Pulmonary Disease Treatment Devices Market in APAC (2019-2027)

Table 22: Chronic Obstructive Pulmonary Disease Treatment Devices Market in APAC by Country (2019-2027)

Table 23: Chronic Obstructive Pulmonary Disease Treatment Devices Market in China (2019-2027)

Table 24: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Japan (2019-2027)

Table 25: Chronic Obstructive Pulmonary Disease Treatment Devices Market in India (2019-2027)

Table 26: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Australia (2019-2027)

Table 27: Chronic Obstructive Pulmonary Disease Treatment Devices Market in South Korea (2019-2027)

Table 28: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Rest of APAC (2019-2027)

Table 29: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Rest of World (2019-2027)

Table 30: Chronic Obstructive Pulmonary Disease Treatment Devices Market in RoW by Region (2019-2027)

LIst of Figures

Figure 1: Competitive Analysis

Figure 2: COVID-19 Impact Analysis

Figure 3: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global (2019-2027)

Figure 4: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global by Product Type (2019-2027)

Figure 5: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global by End User (2019-2027)

Figure 6: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global by Geography (2019-2027)

Figure 7: Chronic Obstructive Pulmonary Disease Treatment Devices Market in North America (2019-2027)

Figure 8: Chronic Obstructive Pulmonary Disease Treatment Devices Market in North America by Country (2019-2027)

Figure 9: Chronic Obstructive Pulmonary Disease Treatment Devices Market in the US (2019-2027)

Figure 10: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Canada (2019-2027)

Figure 11: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Mexico (2019-2027)

Figure 12: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Europe (2019-2027)

Figure 13: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Europe by Country (2019-2027)

Figure 14: Chronic Obstructive Pulmonary Disease Treatment Devices Market in France (2019-2027)

Figure 15: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Germany (2019-2027)

Figure 16: Chronic Obstructive Pulmonary Disease Treatment Devices Market in the United Kingdom (2019-2027)

Figure 17: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Italy (2019-2027)

Figure 18: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Spain (2019-2027)

Figure 19: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Russia (2019-2027)

Figure 20: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Rest of Europe (2019-2027)

Figure 21: Chronic Obstructive Pulmonary Disease Treatment Devices Market in APAC (2019-2027)

Figure 22: Chronic Obstructive Pulmonary Disease Treatment Devices Market in APAC by Country (2019-2027)

Figure 23: Chronic Obstructive Pulmonary Disease Treatment Devices Market in China (2019-2027)

Figure 24: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Japan (2019-2027)

Figure 25: Chronic Obstructive Pulmonary Disease Treatment Devices Market in India (2019-2027)

Figure 26: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Australia (2019-2027)

Figure 27: Chronic Obstructive Pulmonary Disease Treatment Devices Market in South Korea (2019-2027)

Figure 28: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Rest of APAC (2019-2027)

Figure 29: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Rest of World (2019-2027)

Figure 30: Chronic Obstructive Pulmonary Disease Treatment Devices Market in RoW by Region (2019-2027)

Figure 31: Market Drivers

Figure 32: Market Barriers

Figure 33: Marker Opportunities

Figure 34: PORTER'S Five Force Analysis

Koninklijke Philips N.V.
Omron Healthcare, Inc.
Aerogen
PARI GmbH
GF Health Products, Inc.
BMC Medical Co., Ltd
Medtronic PLC
Invacare Corporation
Trudell Medical International
Nouvag AG
Timesco Healthcare Ltd.
LAICA S.p.A.
Vega Technologies Inc.
Besco Medical Limited
DeVilbiss Healthcare LLC
Feellife Health Inc.
Wellinks
Rossmax International Ltd.
Novartis AG
AstraZeneca
GlaxoSmithKline plc
Lupin, Zydus Cadila
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH
Glenmark Pharmaceuticals Limited
LepuMedical Technology (Beijing) Co.,Ltd
Promed Technology Co. Limited
HELTMAN Medikal A.S.
Pneuma Respiratory
Cipla Inc
Microlife Corporation
Honsun

 

Forward to Friend

Need A Quote